Wraparound obesity care pushed GLP-1 weight loss far beyond medication alone
A two-year real-world analysis from Withings Health Solutions and Calibrate Health found that GLP-1 treatment produced substantially stronger weight loss when it was paired with integrated obesity care rather than used as a stand-alone prescription. After statistical adjustment for baseline differences, adults enrolled in Calibrate lost 17.3% of starting body weight at two years, compared with 10.7% among GLP-1 users outside the program. The relative gap exceeded 60%.
The finding lands in the middle of a growing debate over how obesity care should be purchased and delivered. Employers and health plans have been eager to cover GLP-1 drugs because of their strong efficacy, but the medication itself does not address the full biology and behavior of chronic weight regulation. Appetite suppression can initiate weight loss, yet maintenance depends on sleep, food intake, activity, side-effect management, adherence, and the metabolic consequences of losing both fat and lean tissue. The Withings-Calibrate data suggest that the care architecture around the prescription may determine whether those early gains persist.
Continuous monitoring captured the full weight-loss arc
The cohort included 4,961 U.S. adults who started GLP-1s between 2022 and 2024. Calibrate accounted for 3,422 members, while 1,539 Withings users took GLP-1s without the program. Because enrollment into Calibrate was voluntary, the two groups were not identical at baseline. The comparison therefore relied on adjustment for age, sex, race, body mass index, comorbid conditions and GLP-1 treatment before drawing outcome comparisons.
Weight was tracked through daily weigh-ins from Withings-connected scales over more than 24 months, giving the investigators a much denser view than sporadic clinic visits can provide. The data did not just show how much weight came off; they showed when loss slowed, when regain began, and how much of the initial response was retained. In obesity medicine, those inflection points matter because treatment failure often emerges gradually, long before it becomes obvious on a quarterly chart review.
A single clinic weight can miss the most important part of the story: the rebound.
By the end of follow-up, Calibrate members remained about 16.6% below baseline even after some regain. The GLP-1-only group reached a best point of 12.6% loss and settled at about 9.2% below baseline at the peak of its rebound. The pattern suggests that a structured program may help blunt the regression that commonly follows the first phase of pharmacologic weight loss, when appetite control and novelty effects start to fade and day-to-day behaviors regain influence.
Lean mass and fat loss moved in different directions
The study also examined body composition in a subgroup of 974 participants followed for that endpoint. In that analysis, the muscle-to-fat ratio improved 49.3% in Calibrate members versus 39.9% in GLP-1-only users at 18 months, a roughly 9-point difference. Body composition follow-up included 520 Calibrate members and 454 Withings users.
That distinction has direct metabolic implications. Weight reduction driven largely by fat loss is not the same as weight reduction that includes meaningful lean mass depletion. Muscle is not inert tissue; it contributes to glucose disposal, energy balance and functional reserve. If a patient loses too much muscle while pursuing rapid weight loss, the net result can be weaker metabolic health even when the scale looks encouraging. The Withings data imply that body composition tracking can identify when the therapeutic balance is drifting in the wrong direction, allowing nutrition and resistance training guidance to be tightened before the program veers off course.
In practice, the number on the scale can mask the quality of the loss. A program that preserves more lean mass while still driving a larger overall reduction may produce a more durable metabolic benefit than medication alone.
Personalized obesity treatment worked like chronic disease care
Calibrate framed the result as evidence that obesity should be managed as a chronic disease rather than a medication-only problem. The program combines physician-led evaluation, medication optimization, coaching and continuous monitoring. Before treatment begins, members undergo a comprehensive clinical review rather than a brief questionnaire, and lab data help define the baseline metabolic profile. That information then informs individualized care from the start.
The coaching model centers on four pillars: nutrition, activity, sleep and mindset. Side-effect management and anticipatory guidance are built into the workflow, which may help with persistence on treatment. In a disease such as obesity, adherence often deteriorates when early symptoms, dose changes or life stressors are handled piecemeal. A structured care path can close those gaps and keep treatment aligned with the patient’s real-world experience.
Linda Anegawa, Calibrate Health’s chief medical advisor, drew the comparison to hypertension and type 2 diabetes, where medication alone is rarely enough to control the condition over time. The parallel is clinically apt. Chronic metabolic disease responds best when treatment is paired with self-monitoring, behavior support and frequent course correction, not simply a refill.
Connected devices turned sparse follow-up into continuous data
Withings and Calibrate have worked together for more than five years, and the collaboration became a formal study after repeated use of connected scales revealed patterns worth measuring at scale. Antoine Pivron, vice president of Withings Health Solutions, argued that most GLP-1 users are still monitored through a narrow clinical keyhole: a few office weights each year, each one influenced by clothing, hydration, meals and the timing of the visit. Between appointments, the clinician often has no visibility into plateaus, regain or discontinuation.
Connected scales change that dynamic by generating a stream of measurements instead of isolated snapshots. The body composition signal adds another layer, making it possible to distinguish fat loss from muscle loss and to identify emerging risk patterns, including the possibility of hypertension. Pivron stressed, however, that a risk score alone is not enough. A device alert has to sit inside a care protocol with confirmation, clinical review and a defined next step. Without that structure, the data only create noise.
The cost question remains open despite better clinical outcomes
The study did not evaluate healthcare spending, even though cost remains central to employer and payer decisions about GLP-1 coverage. Employers are facing rising healthcare costs, and GLP-1s are a major driver of that pressure. Calibrate pointed to separate data suggesting metabolic improvements that could translate into lower spending, including a reported 80% normalization of glycemia among members with diabetes or prediabetes at one year, 79% normalization of abnormal ALT, and 68% normalization of elevated triglycerides. The company also said 82% of members with high work-related burden no longer reported it at one year, while 90% described improved quality of life and 94% said their health was better than a year earlier.
Those outcomes are clinically plausible, but the present analysis stops short of proving economic return. The central unresolved issue is not whether integrated obesity care can improve weight loss; this study suggests it can. The harder question for payers is how those gains translate into claims, utilization and long-term spending when the program is delivered at scale. For now, the data support a straightforward operational conclusion: a GLP-1 prescription without monitoring, coaching and metabolic oversight is an incomplete intervention, and the weight-loss response is likely to be smaller and less durable than one delivered inside a full care model.